The University of Chicago Header Logo

Connection

Kathleen Mullane to Female

Back to Details
This is a "connection" page, showing publications Kathleen Mullane has written about Female.
Kathleen Mullane
Connection Strength
0.421
Female
  1. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2019 09; 19(9):1001-1012.
    View in: PubMed
    Score: 0.032
  2. A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019 01 07; 68(2):196-203.
    View in: PubMed
    Score: 0.031
  3. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018 Aug; 61(8):518-533.
    View in: PubMed
    Score: 0.030
  4. Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host. Transpl Infect Dis. 2016 Oct; 18(5):785-790.
    View in: PubMed
    Score: 0.027
  5. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 10; 71(10):2964-71.
    View in: PubMed
    Score: 0.026
  6. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1435-40.
    View in: PubMed
    Score: 0.024
  7. Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults. J Infect Dis. 2013 Nov 01; 208(9):1375-85.
    View in: PubMed
    Score: 0.021
  8. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013; 38(1):1-11.
    View in: PubMed
    Score: 0.021
  9. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 Sep; 53(5):440-7.
    View in: PubMed
    Score: 0.019
  10. Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transpl Infect Dis. 2007 Jun; 9(2):89-96.
    View in: PubMed
    Score: 0.014
  11. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020 09 15; 324(11):1048-1057.
    View in: PubMed
    Score: 0.009
  12. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. N Engl J Med. 2020 11 05; 383(19):1827-1837.
    View in: PubMed
    Score: 0.009
  13. Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: A preliminary report. J Clin Exp Neuropsychol. 1999 Oct; 21(5):730-5.
    View in: PubMed
    Score: 0.008
  14. Misdiagnosis of Bordetella bronchiseptica Respiratory Infection as Bordetella pertussis by Multiplex Molecular Assay. Clin Infect Dis. 2018 11 28; 67(12):1919-1921.
    View in: PubMed
    Score: 0.008
  15. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 02; 25(2):369-381.
    View in: PubMed
    Score: 0.008
  16. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 05 26; 391(10135):2116-2127.
    View in: PubMed
    Score: 0.007
  17. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Mycoses. 2018 Jul; 61(7):485-497.
    View in: PubMed
    Score: 0.007
  18. Impact of unresolved neutropenia in patients with neutropenia and invasive aspergillosis: a post hoc analysis of the SECURE trial. J Antimicrob Chemother. 2018 03 01; 73(3):757-763.
    View in: PubMed
    Score: 0.007
  19. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N Engl J Med. 2017 12 21; 377(25):2433-2444.
    View in: PubMed
    Score: 0.007
  20. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017 Dec 01; 72(12):3406-3413.
    View in: PubMed
    Score: 0.007
  21. The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. Infect Control Hosp Epidemiol. 2017 11; 38(11):1351-1357.
    View in: PubMed
    Score: 0.007
  22. Serological positive markers of hepatitis B virus in femoral venous blood or umbilical cord blood should not be evidence of in-utero infection among neonates. BMC Infect Dis. 2016 08 12; 16(1):408.
    View in: PubMed
    Score: 0.007
  23. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016 Jul; 16(7):828-837.
    View in: PubMed
    Score: 0.006
  24. Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis. 2016 Mar 01; 62(5):596-602.
    View in: PubMed
    Score: 0.006
  25. Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS One. 2015; 10(6):e0129022.
    View in: PubMed
    Score: 0.006
  26. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1441-5.
    View in: PubMed
    Score: 0.006
  27. Reply to M.R. Green et al. J Clin Oncol. 2013 Dec 01; 31(34):4379.
    View in: PubMed
    Score: 0.005
  28. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26; 369(13):1227-36.
    View in: PubMed
    Score: 0.005
  29. Histoplasmosis after solid organ transplant. Clin Infect Dis. 2013 Dec; 57(11):1542-9.
    View in: PubMed
    Score: 0.005
  30. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 01; 31(19):2493-9.
    View in: PubMed
    Score: 0.005
  31. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013 Mar 25; 13:148.
    View in: PubMed
    Score: 0.005
  32. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug; 55 Suppl 2:S121-6.
    View in: PubMed
    Score: 0.005
  33. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 03; 364(5):422-31.
    View in: PubMed
    Score: 0.004
  34. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009 Jan; 53(1):223-8.
    View in: PubMed
    Score: 0.004
  35. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant. 2007 Apr; 39(7):425-9.
    View in: PubMed
    Score: 0.003
  36. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006 Jan; 50(1):126-33.
    View in: PubMed
    Score: 0.003
  37. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis. 2005 Oct; 24(10):654-61.
    View in: PubMed
    Score: 0.003
  38. Recombinant urokinase for restoration of patency in occluded central venous access devices. A double-blind, placebo-controlled trial. Thromb Haemost. 2004 Sep; 92(3):575-82.
    View in: PubMed
    Score: 0.003
  39. Impaired phagocyte oxidative capacity in patients with human immunodeficiency virus infection. J Lab Clin Med. 1998 Oct; 132(4):284-93.
    View in: PubMed
    Score: 0.002
  40. Information processing and antiretroviral therapy in HIV-1 infection. J Int Neuropsychol Soc. 1998 Jul; 4(4):329-35.
    View in: PubMed
    Score: 0.002
  41. Working memory deficits in HIV-seropositive drug users. J Int Neuropsychol Soc. 1997 Sep; 3(5):451-6.
    View in: PubMed
    Score: 0.002
  42. Delayed recognition memory span in HIV-1 infection. J Int Neuropsychol Soc. 1995 Nov; 1(6):575-80.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.